Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 8, 2008

View Archived Issues

Nuclear orphan receptor Nur77 can be targeted with cytosporone B

Amgen targets BKCa channel for migraine treatment

Wyeth creates novel series of selective norepinephrine reuptake inhibitors

Federal Trade Commission clears Frensenius' acquisition of APP Pharmaceuticals

Debiopharm and EPFL initiate research project Debio 0826 in cancer

Evotec achieves third milestone under drug discovery contract with Boehringer Ingelheim

Dr. Reddy's signs agreements with Antares and Cosmederm for dermatology products

Preclinical study with AZD-6140 shows antiplatelet effect in a canine model of coronary thrombosis

Acucela and Otsuka establish codevelopment agreement for rebamipide

SIGA awarded contract to develop new smallpox indications for ST-246

Human Genome Sciences and Hospira sign manufacturing process development deal

Epix to regain worldwide commercialization rights to Vasovist

Priority review for ATryn BLA

Emergent receives USD 24 million contract from the HSS to develop AVP-21D9

Camurus and Wyeth sign option and license agreement in hemophilia therapeutics

Novel treatments for respiratory disorders disclosed in recent Merck Frosst patent

BioCryst presents results from BCX-4208 phase IIa trial in psoriasis

BioMS Medical's dirucotide granted FDA fast track for multiple sclerosis

Idenix reports results from proof-of-concept study for IDX-899 in HIV

Recent patents describe new treatment options for immunological disorders

ProtAffin granted FDA orphan drug designation for PA-401 in transplantation

Novel antiinflammatory agents claimed in recent Boehringer Ingelheim patent

Toctino (alitretinoin) receives marketing authorization in the U.K.

Yaz, a new low-dose oral contraceptive, launched in Europe by Bayer Schering Pharma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...